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A model was designed to examine the relations between
incremental costs and benefits of coronary thromboly-
sis/reperfusion therapy. The model allows for the study
of intravenous and intracoronary streptokinase, intra-
venous tissue plasminogen activator and primary angio-
plasty, Three strategies for the management of reocclu-
sion are also compared.
It was found that each of the following four variables
can be responsible for a 2- to IS-fold variation in the
costs per additional survivor: I) the quantity of jeop-
ardized myocardium, 2) the duration of coronary occlu-
sion before the onset of therapy, 3) the time required
from the onset of therapy until reperfusion is achieved,
and 4) the reocclusion management strategy.
Therapeutic strategies involving intravenous admin-
istration of thrombolytic agents were found to be COIl-
Recent randomized trials (1-4) with thrombolytic agents.
in which patients were treated early in the course of acute
myocardial infarction, demonstrate clear benefits in survival
and left ventricular ejection fraction. However, questions
regarding the subsets of patients most likely to benefit. the
relation between the time after the onset of symptoms at
which reperfusion is achieved and myocardium salvaged
and the effect of mechanical revascularization on the inci-
dence of reocclusion remain unanswered.
Equally compelling questions relate to the cost of throm-
bolytic therapy. Medical care costs of thrombolytic therapy
include I) the cost of the thrombolytic agents themselves.
and 2) the cost of other procedures and medical care related
to and consequent to thrombolytic therapy, such as prolon-
gation of stay in the coronary care unit and hospital and
increased utilization of percutaneous transluminal coronary
angioplasty and coronary artery bypass grafting. Discrc-
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sistently more cost effective than were strategies involv-
ing intracoronary administration of thrombolytic agents
and primary angioplasty. In patients with a large or
moderate-sized infarct, proper selection of intravenous
protocols and reocclusion management strategies leads
to costs of $7,000 to $IOO,OOO/additional survivor, costs
that are similar to those of many generally accepted
medical practices. Substantially higher costs per addi-
tional survivor are incurred with the routine use of
thrombolytic therapy in patients with a small infarct or
the routine use of coronary artery bypass surgery to
reduce the risk of reocclusion after successful throm-
bolytic therapy. Decisionsregarding which patients should
receive thrombolysis/reperfusion therapy depend on so-
ciety's willingness to pay for its incremental benefits.
(J .4m Coli Cardiol /987:JO:79B-90B)
tionary utilization of these relatively expensive ancillary
procedures can have a profound impact on the total costs
of thrombolytic therapy. Nonmedical care costs includecap-
ital investment induced by increased reliance on thrombo-
lytic therapy, and possible effects on the earnings and
nonmedical expenses of patients.
Thrombolytic therapy thus represents a promising mo-
dality for the treatment of a major illness that has uncertain
benefits and costs. A key question is whether the benefits
of thrombolytic therapy can be obtained at a socially ac-
ceptable cost. The goals of this report arc to develop a cost-
effectiveness model that is based on current information
regarding: the clinical benefits and medical care costs of
thrombolytic therapy, and to use this model to illustrate
some important predictors of its cost effectiveness.
Methods
A model was designed to estimate the benefits of throm-
bolytic therapy in patients having normal left ventricular
function (ejection fraction = 62%) before infarction. The
model is based on a set of assumptions about thrombolysis
that were derived from l ) a review of the literature. and 2)
the results of a questionnaire. available on request, which
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Table I. Risk Factors in Acute Myocardial Infarction*
Anterior wall myocardial infarction
Rules heard over more than the lower one-third of lung fields
Hypotension (systolic blood pressure < I 00 111mHg) with sinus tachycardia
(heart rate> 100 beats/min)
Atrial tachyarrhythrnias
Age > 70 years
*Adapted from the TlMI II protocol.
was completed by seven investigators active in this field
(see Acknowledgment).
The model compares streptokinase, tissue plasminogen
activator produced by recombinant techniques (rt-PA) and
primary coronary angioplasty (angioplasty without preced-
ing thrombolysis) in the establishment of reperfusion. It also
compares intracoronary and intravenous administration of
the two thrombolytic agents, and three strategies for the
prevention of reoccJusion: conservative treatment with an-
ticoagulation, coronary angioplasty and coronary artery by-
pass surgery.
The Model's Principal Assumptions
l) Patient risk stratification. On the basis of findings
obtained by clinical examination on admission, patients can
be assigned to one of three prognostic categories. Patients
who are found to have cardiogenic shock, pulmonary edema
or at least three risk factors used by investigators in the
Thrombolysis in Myocardial Infarction (TIM!) trial (Table
I) are assigned to the large infarct/poor prognosis group.
Patients having one or two of these risk factors are assigned
to the moderate infarct/moderate prognosis group. Patients
without any of these risk factors constitute the small in-
farct/good prognosis group. In the latter group, the in-hos-
pital case fatality rate is assumed to be 3% with standard
care; survivors in this small infarct group arc assumed to
have a chronic phase ejection fraction averaging 52%. The
mortality between hospital discharge and I year is estimated
from the chronic phase ejection fraction. Table 2 shows
parallel assumptions for patients in the other two categories
(5-9).
2) Timing of reperfusion: effect on ejection fraction
and mortality. Clinical benefits resulting from reperfusion
are assumed to depend solely on the elapsed time between
the onset of infarction and reperfusion. It is assumed that
reperfusion occurring ~6 hours after the onset of infarction
salvages negligible quantities of myocardium and therefore
causes no detectable improvement in ejection fraction or in-
hospital survival compared with standard care. Reperfusion
occurring at successively earlier times salvages progres-
sively greater quantities of myocardium and leads to re-
ductions in mortality and improved ejection fraction among
survivors (Table 3) (5, IO~ 14). Compared with the average
ejection fraction of survivors receiving standard care, the
improved ejection fraction attributed to thrombolysis leads
to widening survival benefits in the year after infarction
(5,15,16).
3) Procedural delay, After the patient enters the medical
care system, the time required for diagnosis, commence-
ment of therapy and establishment of reperfusion is I hour
with intravenous thrombolytic agents, 1.5 hours with pri-
mary coronary angioplasty and 2 hours with intracoronary
streptokinase (5,17-23). Procedural delay for secondary
coronary angioplasty (that is, angioplasty used to establish
reperfusion in patients for whom pharmacologic attempts to
establish reperfusion have failed) is 2 hours; with this strat-
egy. it is assumed that patients are taken to the catheter-
ization laboratory immediately after intravenous adminis-
tration of a thrombolytic agent.
Table 4 shows how the preceding assumptions can be
used to estimate the number of additional I year survivors
attributable to thrombolysis/reperfusion therapy in a cohort
of 100 patients with a large infarct. This table illustrates
that the timing of reperfusion depends on the duration of
acute myocardial infarction before hospital arrival (column
I) and the choice of protocol for the establishment of re-
perfusion (column 2). In-hospital mortality (column 3) and
chronic phase left ventricular ejection fraction (column 4)
depend on infarct size and reperfusion time. As before, the
mortality between hospital discharge and I year (column 5)
is estimated from the chronic phase ejection fraction. When
the total first year mortality using thrombolysis/reperfusion
therapy (column 6) is subtracted from the total first year
mortality using standard care (Table 2), the incremental
survival (survival attributable to the use of thrornboly-
sis/reperfusion therapy) is obtained.
Table 5 depicts parallel estimates for the additional num-
ber of I year survivors in the moderate and small infarct
Table 2. In-Hospital and I Year Mortality After Acute Myocardial lnfarction
Infart
Size
Large
Moderate
Small
In-Hospital
Mortality
(%)
40
12
3
Mean LVEF
(%) in
Survivors
27
42
52
Additional
Deaths in
Year I
12
6
4
Total First
Year Mortality
(%)
52
18
7
LVEF = left ventricular ejection fraction.
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Table 3. Effect of Successful Reperfusion on Chronic Phase Left Ventricular Ejection Fraction
and In-Hospital Mortality in Acute Myocardial Infarction
Hour.; Bc:wccn AMI Onse: and Rcpcrtus.on
- - - - -
- - - - - - -------------- - - - -----_._ ---
Global LVEF (% salvage)
In-hospital mortality ( Co'; reduction)
90
(>()
70
50
50
40
30
.10
J()
15
o
o
AMI - acute myocardial infarction; LVE!' left ventricular ejection fraction.
groups. These estimates represent maximal or ideal benefits
attributable to thrornbolysis/reperfusion therapy. because they
do not account for three factors that effectively diminish the
true benefits: thrombolytic efficacy, treatment-associated
mortality. and reocclusion. These characteristics arc incor-
porated into the model as follows:
4) Thrombolytic efficacy. It is assumed that optimal
doses of intracoronary streptokinase establish reperfusion in
80% of cases (5, 17.24) . Intravenous rt-PA is 84% effective
in achieving recanalization when administered immediately
after coronary thrombosis; its efficacy diminishes linearly
to 67% by 6 hours (5. 18. [9) . The efficacy of intravenous
streptokinase similarly diminishes from 6lJ to 3Ylc in the 6
hours after the onset of infarction (5.20.2 1). Eighty percent
of patients with acute infarction are assumed to be suitable
for primary coronary angioplasty because of the presence
of a total or near total proximal occlusion in the infarct-
related artery (5.22 ,23). Primary angioplasty is 95% effec-
tive in establishing reperfusion in suitable patients (5,22,23).
5) Treatment-associated mortality. It is assumed that
these are as follows: streptokinase/heparin and rt-PA'hepa-
rin = O.57c (I~5.17.l9); primary or secondary angioplasty
= 0.790 (5.25); secondary coronary artery bypass surgery
= 1.5ck (5,26).
6) Reocclusion, It is assumed that reocclusion causes
the loss of all salvaged myocardium and of all benefits
attributable to thrombolysis (27-29). Using conventional
anticoagulation after thrombolytic therapy. the reocclusion
rate is 23% (5.27-30). Coronary arteriography can be used
to stratify patients according to the risk of rcocclusion
(5,31.32). The high risk group, having greater than 70r.Ic,
residual obstruction in the infarct-related artery . constitutes
SOlle of the patient group with successful reperfusion and
has a 30/f{ risk of reocc lusion (5,33.34). The remaining
Table 4. The Calculation of Maximal Benefits Attrihutahle to Thrornbolysis/Repcrfusion Therapy (the large infarct group)"
Time (hi
Between Onset
of Symptoms and
Patient Arrival
o
2
3
Mortality
Strategy to in-Hospital
Achieve Mortality Chronic Hospital Discharge Total First Incremental
Repertusion ('7<1 LVEF( CJrj to I Year (CJr) Year (' Ir) Survival
--- ---
Iv proiocn ls 12 60 .1 15 .17
r PTeA 14 59 3 17 35
Ic SK In 59 3 19 3.1
lv protocols 16 59 3 19 .1 .1
1° PTCA IS 55 4 21 .'I I
Ie SK 20 52 4 2 .~ 21)
lv protocols 20 52 4 23 2<)
I" PTCA 22 4S :; 27 26
Ie SK 24 45 6 29 2.'
Iv protocols 24 45 6 29 23
I" PTCA 26 42 7 .'13 1<,)
Ic SK IS J9 S :'6 !IJ
Iv protocols 2R .1 9 X .1(, 16
1° IYfCA 34 34 12 42 <)
Ie SK 411
.' I 15 ·W .1
Iv protocol» :'4 .\1 15 49 3
I" PTCA
.' 7 29 I ii 51 I
Ie SK 40 27 20 :'~ 0
._- - -
" Incrernental survival is expressed ;1' the additional number of I year survivors for every 100patients successfully treated with rhrombolysis/rcperf usicn
therapy. Calculations do not account for thromholync efficacy. treatment-associated mortality or reocclusion. lc -e- intrucoronary: Iv ~- intravenous;
LVEf< = left ventricular ejection fraction: £'TCA '0 percutaneous transluminal coronary angioplasty; SK = streptokinase: 10 = primary.
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Table S. Maximal Benefits Attributable to Thrornbolysis/Rcpcrfusion Therapy"
Time fhrl Incremental Survival
Between Onset of Strategy to
Repertusion and Achieve Large Moderate Small
Patient Arrival Reperfusion Infarct Infarct Infarct
0 tv protocols 37 14 4
1° PTCA 3:- 13 4
tc SK 33 13
"
lv protocols 3." 13 4
1° PTCA 31 II 4
Ie SK 19 10 3
1 lv protocols 19 10 :1
IVfYTCA 16 is 1
I,' SK 1.' 6 1
, Iv protocols 13 6 1
.'
I" PTCA 19 5 1
k SK 16 4 1
4 lv protocols 16 4 1
I" fYTCA <} 3 I
lc SK 3 1 < I
5 tv protocols 3 1 < I
(" lyrCA I < I < I
k SK 0 0 0
" Incremental survival is expressed as the additional number of I year survivors fnr every 100 patients
successfully treated with thrombnlysis/reperfusion therapy. Calculations do not account for thrombolytic effi-
cacy. rreatrnent-ussociared mortality or reocclusion, Abbrcviuuons as in Table 4.
Table 6. Incremental Costs of Thrombolytic Therapy
( t9X6 dol lars)"
".All figure, include physician fees. CARl. = coronary artery bypass
surgery: rL· PA = recombinant tissue-type plasminogen activator: for other
abbreviations sec Table 4.
The Decision Tree
Four treatment strategies were compared with standard
care (Table 7):
moderate infarct involves only the administration of sub-
cutaneous heparin, whereas standard care of patients with
a large infarct involves continuous intravenous heparin for
5 days. After administration of thrombolytic therapy. all
patients receive 5 days of intravenous heparin. Therefore,
there are no incremental costs of anticoagulants for patients
with a large infarct who receive thrombolytic therapy.
$
o
600
5()()
15 00
1,000
1.5 ll0
5.11KJ
Iti.IKJO
Treatment
Anticoagulation
Large inIarct
Small/moderate infarct
Iv streptokinase
Iv rt-PA
Coronary angiography
lc streptokinase
PTCA
CAAG
20% of patients with lesser or no residual obstruction of the
infarct-related artery have a 3% risk of reocclusion.
Mechanical revascularizution reduces the risk of reoc-
elusion in high risk patients (5.26,35-38) . It is assumed
that 80% of high risk patients are suitable for secondary
coronary angioplasty. and in such patients angioplasty is
successful in 95% (15.16). After successful secondary an-
gioplasty, the risk of reocclusion is reduced from 30 to 10%
(5.3n- 38l. If angioplasty is unsuccessful, the risk of reoc-
elusion rises from 30 to 40% (5.36- 38), All high risk pa-
tients are suitable for coronary art ery bypass surgery. The
incidence of reocclusion after such surgery is 2% (5,39).
7) Incremental costs ofthrombolysis/reperfusion ther-
apy. Estimates for the incremental costs of thrornboly-
sis/reperfusion therapy appear in Table 6. To obtain these
estimates, Brigham and Women's Hospital charges and phy-
sician fees for 1986 were determined and then converted to
resource costs using the appropriate ratio of charges to costs.
An additional $700/patient was subsequently added to ac-
count for increased intensity of care associated with the use
of thrombolysis/reperfusion therapy. Increased intensity may
result from a 'prolonged coronary care unit or hospital stay
or an increase in the utilization of cardiac medications and
laboratory' tests. The cost of rt-PA was estimated because
it has not been established at the time of this writing.
To calculate the incremental costs o( anticoagulation, it
is assumed that standard care in patients with a small or
,lACe Vol. lIJ, 'ill :;
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Abbreviations as in Tables 4 and 6.
Table 7. Strategies for the Usc of
Thrombolysis/Repcrfusion Therapy
1412
2A-3
• rv SK
.• Ie SK
3-3
10
26-3
~=--__--- rI- PA26-2
B6
26-1
2A-2
.4 .....•..
.·-2A-I .. -
. •... 3-2
3-1
42
o
o
patients who are unsuitable for angioplasty receive coronary
artery bypass surgery.
Substrategy 3. All high risk patients receive coronary
artery bypass surgery.
3) lntracoronary streptokinase. This strategy is iden-
tical to the aggressive intravenous protocol except that the
thrombolytic agent is administered through the intracoronary
route.
4) Primary coronary angioplasty. This strategy in-
volves immediate coronary arteriography and angioplasty
in all suitable patients. Unsuitable patients receive intra-
coronary streptokinase.
In comparing any two of these strategies. the marginal
cost per 1 year survivor is the difference between the costs
of the two strategies (in dollars) divided by the difference
in their benefits (in number of I year survivors). A pref-
erence for the more effective (and more costly) strategy
implies a willingness to pay at least an amount equal to the
marginal cost per additional survivor gained by the more
effective strategy.
Statistics. Data analysis was performed on a Corona
personal computer using SMLTREE decision analysis soft-
ware.
Choice of Strategy FJr the Administration 01'
Thrombolytic Therapy
In general. increasingly invasive reocclusion manage-
ment protocols are associated with increasing marginal hen-
Results
INCREMENTAL COSTS (K$I,OOOJ
Figure I. Costs and benefits of thrombolysis/repcrfusion therapy
(large infarct: patients arrive 2 hours after onset of acute myocardial
infarction). ic -- intracoronary: iv = intravenous; rt-PA = re-
combinant tissue-type plasminogen activator; SK = streptokinase.
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Conservative lv SK
Conservative lv rt-PA
Aggressive Iv SK
Followed by PTCA
Followed by PTCA and CABG in patients with
unsuccessful PTCA or those unsuitable for PTCA
Followed by CABG
Aggressive lv rt-PA
Followed by PTCA
Followed by PTCA and CABG in patients with
unsuccessful PTCA or those unsuitable for PTCA
Followed by CABG
1c SK
Followed by VrCA
Followed by PTCA and CABG in patients with
unsuccessful PICA or those unsuitable fIJI' PTCA
Followed by CABG
Primary PTCA
2A-3
2B
2B-1
2B-2
2B-3
3-1
,-~
3-3
4
3
IA
IB
2A
2A-1
2A-2
1) Intravenous administration of a thrombolytic agent
(streptokinase or rt-Pa) with conservative reocclusion
management; In this strategy, eligible patients receive the
thrombolytic agent intravenously followed by heparin. Car-
diac catheterization is performed only in patients having
postinfarction angina or a positive predischarge exercise
tolerance test. It is assumed that, among patients not re-
ceiving thrombolytic therapy, the fraction of patients
undergoing catheterization for these indications is 70, 40,
and 20% for those with a large, medium and small infarct.
respectively (5,39). After thrombolytic therapy. these per-
centages rise to 90, 70, and 50%, respectively, because
patients with successful reperfusion have a high risk of
developing these conditions.
2) Intravenous administration of a thrombolytic agent
with aggressive reocclusion management. This strategy
involves coronary angiography immediately after intrave-
nous administration of the thrombolytic agent. Its objectives
are twofold: I) To identify patients having persistent oc-
clusion of the infarct-related artery despite the administra-
tion of a thrombolytic drug; these patients can then be sub-
jected to secondary angioplasty if they are suitable candidates.
2) To identify patients with successful reperfusion who are
at high risk for reocclusion. These patients become candi-
dates for aggressive interventions such as coronary angie-
plasty and bypass surgery to reduce this risk. Three sub-
strategies toreducetheincidenceof reocclusion are considered:
Substrategv f. Secondary coronary angioplasty is per-
formed in all suitable patients considered to be at high risk
for reocclusion. High risk patients who arc unsuitable for
angioplasty receive anticoagulants.
Substrategy 2. This is similar to substrategy I except
that patients with unsuccessful angioplasty and high risk
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Willingness to pay for an
additional year of tife 1-_--
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28-3
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28-2
Standard core
10,000,000
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100,000~------------=
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1,000
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I
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Duration of infarction (hours) Duration 01 .nforchon ( hours)
10,000,000
Figure 2. Optimal treatment strategies for patients with a large
(A), moderate (B) or small (C) infarct.
Optimal strategy
Durolion of inforclion I hours I
sion management with heparin (strategy I A), and all four
strategies involving the use of intravenous rt-PA. Prefer-
ences among these five intravenous protocols depend on
infarct size, the duration of infarction before hospital arrival
and the willingness to pay for an additional survivor from
acute myocardial infarction (Fig. 2A to C).
Optimal choices. To demonstrate how these figures can
be used, suppose one is willing to pay $100,OOO/additional
I year survivor of acute myocardial infarction, a figure that
is similar to the cost-effectiveness of some other generally
accepted medical practices (4~42). Among patients pre-
senting to the health care system 2 hours after the onset of
infarction, Figure 2A demonstrates that one would prefer
to obtain the relatively substantial benefits of intravenous
rt-PA followed by angioplasty (strategy 28-1) in patients
with a large infarct. For those with a moderate infarct,
Figure 2B demonstrates that the optimal choice is intrave-
nous rt-PA followed by heparin (strategy IB) and its more
modest benefits. Figure 2C demonstrates that, for patients
with a small infarct, one would not choose any form of
thrombolysis/reperfusion therapy because the incremental
benefits are so small.
Secondary Relations and Sensitivity Analysis
Thrombolytic therapy's benefit/cost relations may be af-
fected by numerous factors, some of which are illustrated
in Table 8. This table demonstrates many combinations of
infarct size, arrival time in the emergency ward and reoc-
elusion management strategy and their combined effects on
two variables: I) incremental survival, that is, the additional
432
lA
18
2B-1
28-2
Standard core
B o~----'----'-------'-----'
10,000
1,000
100,000
Willingness to pay for On
additional year of life
i in dollars, log score)
1,000,000 b-------------
28-3
efits and rapidly increasing marginal costs. This may be
seen, for example, by examining the incremental benefits
and costs of strategy 3-3 (intracoronary streptokinase fol-
lowed by coronary artery bypass surgery) compared with
strategy 3-1 (intracoronary streptokinase followed by an-
gioplasty) (Fig. I).
Intravenous protocols. Five intravenous protocols yield
more additional survivors per dollar spent than do either
intracoronary streptokinase (strategies 3-1, 3-2 and 3-3) or
primary angioplasty (strategy 4). These results hold for all
groups of patients and are illustrated for the large infarct
group in Figure I. The five superior protocols include in-
travenous streptokinase followed by conservative reocclu-
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number of I year survivors attributable 10 thrornboly-
sis/reperfusion therapy, and 2) the cost/benefit ratio.
Infarct size. The cost of thrombolytic treatment is 7 to
15 times greater per additional I year survivor for patients
having a small infarct than for patients with a large infarct.
For example, when rt-P:'\. and heparin (strategy 18) arc used
to treat patients presenting to the health care system 2 hours
after the onset of infarction. the cost per additional I year
Ta ble 8. Thnunbolysis/Repcrtusion Therapy: Im:rcl11cntal Survival and the Cos t (in thousands or dollars) pL'r Additional Survivor"
Hour, A fl~ r Myocardial lnfarction
- --- - - - - - - - - - - --- - - - - --- - - -- - ---
n
. ._._- . -- - - --
- - - _ . ._-_•._ - - --
- -------_ . - ---
Srrurcgy
IA
2A· 1
2A·2
2A-3
Incremental
Survival
19
7
3
1
Co,1 per Additional
Survivor
7
Incremental
Survival
l .argc Infarct'
12
7
I
I
Cost per Additional
Survivor
12
.I{)
3."
S3
Incremental
Survival
5
2
I
< I
Cos t per Additional
Survivor
27
X6
95
'I'
I H 24 \I 17 I i X 3{)
2H- 1 6 21 S 2X 2 6{)
213-2 2 27 36 1 73
213-3 4S S7 < I 110
3-1 26 24 IX 35 2 2(,l)
3-2 2 3I I 44 < I 34<1
.\ -3 46 I bll < 1 5{),)
.:+ 17 20 20 27 6 ii3
~_._ - ,_._-- ------_._.
Mod e rate Infarcts
... .._ ..._- ---.._ --
- -- -- - -
- _.._---- . ...- -- - _._--_.
- - - - ---- - '- -
IA 7 4U 4 51! I I II
2"\ -1 3 63 I I II: I 2'14
2:\-2 < I N I 1 2 ,~ -: -I 3.'9
2:\ ·3 < \ 125 < I II) I < I 472
113 II 42 5 h:'i 2 15X
2B- 1 2 66 I 101 I 244
2B-2 I X4 ,: 1 \ 27 <: I 302
2B-3 < I 136 I 201 <.1 467
3-1 10 74 S 14(, 2 439
3-2 < I ll2 · . 1 I X-1 <. 1 552
3-.' <. 1 1.'1 - . 1 27.\ < I X20
4 9 M 5 112 2 2hX
- - - ' . ---- ----- - - - - - -----
Small Int urcts
IA 2 108 I 205 <. \ 6X2
2A-I I IYX 1 .U X < I 1.111
2A·2 < I 2.'iO ' . 1 4111 < I 1.2/1 -1
2:\ -3 < I 384 < I hl.1 < I 1.790
I B 2 132 , 22-1 I 631
2B- 1 I 20S " -1 .\ '1 < I 9Sh
2B-2 < I 267 < I ·C (, < I l.lX4
28-3 < I 394 -·: 1 675 <i l .ii34
3-1 3 2,7 2 .\ XI < I 1,460
3-2 < I 29K <' I J 7
'
J < I I .H3H
3-.1 < I 444 < I 713 < I 2.7J3
4 198 .II S lJX X
*Inercmcntal survival is estimated versus standard care or the immediately preceding strategy within each family of protocols, Strategies are defined
in Table 7.
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survivor is $15,000 in those with a large infarct and $224,000
in those with a small infarct (Table 8),
Time of presentation to the health care system.
Thrombolytic treatment of patients arriving 4 hours after
onset of myocardial infarction costs three to seven times
more per additional 1 year survivor than that for patients
already hospitalized at the time of infarction. For example,
among patients with a moderate-sized infarct who receive
rt-PA followed by heparin, the cost per additional survivor
is $42,000 in patients already hospitalized at the time of
infarction and $158,000 in patients who arrive 4 hours after
onset of infarction,
Procedural delay. Although intracoronary protocols are
highly efficacious in establishing reperfusion in acute myo-
cardial infarction, strategies involving their use are two to
five times more costly per additional survivor than are in-
travenous protocols. For example, the use of rt-PA followed
by angioplasty (strategy 2B-I) in patients with a large infarct
who present to the health care system 4 hours after the onset
of infarction is associated with a cost per additional survivor
of $60,000. A similar strategy involving intracoronary strep-
tokinase (strategy 3-1) costs $269,000/additional survivor.
Management of reocclusion. Although the most ag-
gressive protocols, involving coronary artery bypass surgery
to reduce the risk of reocclusion, are associated with the
highest benefits, strategies involving its routine use cost
three to six times more per additional survivor than the
conservative protocols in which anticoagulation with hep-
arin is used. For example, in patients with a moderate infarct
who present to the health care system 2 hours after the onset,
treatment with rt-PA and heparin (strategy IB) costs
$65,OOO/additional survivor, whereas rt-PA followed by
bypass surgery (strategy 2B-3) costs $20! ,000/additional
survivor.
Assuming that these four determinants are independent
of each other, their effects on the cost per additional I year
survivor will be multiplicative. Thus, when intravenous
streptokinase followed by heparin (strategy ! A) is used to
treat hospitalized patients sustaining a large infarct, the cost
per additional 1 year survivor is $7,000. On the other hand,
it is $2,733,000 per additional! year survivor when intra-
coronary streptokinase and bypass surgery (strategy 3-3) is
used to treat patients with a small infarct who present to the
health care system 4 hours after onset of infarction.
Administration protocol and thrombolytic efficacy.
The superior cost-effectiveness of the intravenous protocols
versus that of the intracoronary protocols (Fig. I) is not
sensitive to assumptions regarding the efficacy of intracor-
onary streptokinase. Even if the latter's thrombolytic effi-
cacy is assumed to be 100%, the intravenous protocols have
superior cost-effectiveness ratios. These relations are min-
imally sensitive to assumptions regarding the efficacy of
intravenous thrombolytic agents. If their efficacy were to
decline to 38%, their cost-effectiveness approximates that
of intracoronary streptokinase, but only in the first hour
after onset of infarction. For values greater than 38%, or
for patients arriving 21 hour after the onset of infarction,
the intravenous protocols are more cost-effective.
Primary angioplasty, This may reduce the incidence of
"early" reocclusion (rcocclusion occurring before surgical
revascularization can be undertaken), but it has a procedural
delay \12 hour longer than that of intravenous protocols.
Sensitivity analysis reveals the intravenous protocols to be
more cost-effective even if the early rcocclusion rate after
intravenous therapy approaches 40%.
The cost of thrombolytic therapy. When conservative
reocclusion management with heparin is used, cost/benefit
relations between intravenous streptokinase and rt-PA are
sensitive to the assumed cost of rt-PA. Using our estimate
of $1,500 for the cost of rt-PA, this has a higher cost per
additional I year survivor than intravenous streptokinase.
In this case, the choice between the two conservative strat-
egies depends on infarct size, infarct duration before hospital
arrival and the willingness to pay for an additional survivor
(Fig. 2A to C). However, if the cost of rt-PA is assumed
to be <$1 , 100, then the conservative strategy involving the
more efficacious rt-PA would have a lower cost per addi-
tional survivor than intravenous streptokinase. At this as-
sumed cost there would be no justification. at least on the
basis of the relation between costs and benefits, to choose
intravenous streptokinase.
On the other hand, aggressive protocols utilizing rt-PA.
those in which rt-PA is followed by urgent cardiac cathe-
terization and either angioplasty or surgery, are always more
cost-effective than their streptokinase counterparts, unless
the cost of rt-PA is >$2,800. In the aggressive protocols,
the high cost of ancillary angioplasty or surgery oversha-
dows relatively small cost differences between the two
thrombolytic agents, so that protocol costs are similar re-
gardless of the agent chosen and protocols using the more
efficacious rt-PA are more cost-effective.
Discussion
Cost-effectiveness analyses of medical technologies are
generally undertaken only after the technologies have been
integrated into medical practice. These assessments may not
appreciably influence utilization because established pat-
terns of practice are slow to change, capital has already been
appropriated to make the technology available and trained
personnel participating in the technology may have an in-
terest in its continuation. At the present time. there is great
interest in the use of coronary thrombolysis/reperfusion ther-
apy for the treatment of acute myocardial infarction, but it
has not quite been adopted as a new standard of care and,
to our knowledge, there have been few major capital ex-
penditures or personnel development that might perpetuate
its utilization.
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Factors Affecting Benefits and Costs of
Thrombolytic Therapy
OUf model has identified four variables having critical
impact on the relation between the benefits of thrombolytic
therapy and its costs, Only one, infarct size. is not easily
infl uenced by physicians and others in the health care sys-
tern.
Time of presentat ion to the medical cure system, This
variable may be responsible for a three- to sevenfold vari-
ation in the cost of thrombolytic therapy per additional I
year survivor. It can be reduced through patient education
programs, improved emergency transport systems or the
administration of thrombolytic drugs in the ambulance, at
a first aid stationor even in the patient's home. In our model,
procedural delay is perhaps the most critical determinant
or thrombolytic therapy's cost-effectiveness. Intravenous
protocols consistently outperform intracoronary protocols
(insofar as cost-effectiveness is concerned) despite the lat-
ter' s high efficacy, because the former have a procedural
delay that is I hour shorter. For the same reason intravenous
protocols outperform primary coronary angioplasty. despite
the latter' s assumed high efficacy and assumed ability to
prevent early reocclusion. Increasingly aggressive reocclu-
sion management protocols involving coronary angioplasty
or surgery are associated with greater clinical benefits. but
also with rapidly increasing marginal costs per additional
survivor, especially in patients with a small infarct or in
patients arriving long after the onset of infarction.
The results of this model suggest that[or patients in the
large infarct group who present to the health care system
-S:: 5 hours after the onset of acute infarction, intravenous rt-
PA followed by urgent cardiac catheterization and angio-
plasty (strategy 2B-I) is associated with a marginal cost per
additional survivor that is similar to that of other reasonably
accepted practices such as treatment of mild to moderate
hypertension (40), screening for hypercholesterolemia (41 )
and either dialysis or transplant therapy for end-stage renal
disease (42).
For the moderate infarct group. intravenous rt-PA fol-
lowed by anticoagulant (strategy IB) is also associated with
a cost per I year survivor similar to that of the previously
mentioned medical practices. The routine use of aggressive
rcocclusion management strategies in the moderate infarct
group. especially in patients arriving more than 2 hours after
onset of infarction. is associated with marginal costs per
additional survivor between $100,000 and $500,000.
Patients in the small infa rct gro up have an excellent
prognosis with standard myocardial infarction care. and the
incremental benefits of thrombolysisireperfusion therapy arc
comparatively small. Our model suggests that for patients
in this group. thrombolytic therapy in any form is associated
with costs per additional 1 year survivor that are in excess
of those associated with the previously mentioned medical
practices. For example, the use of rt-PA followed by heparin
in patients with a small infarct who present to the health
care system 2 hours after the onset of acute infarction is
associated with marginal costs of $200.000iadditional sur-
vivor. If coronary artery bypass surgery is used in these
patients to reduce the risk of reocclusion, the marginal costs
rise to over 5600.000 per additional survivor.
The Costs of Thrombolytic Therapy
We have chosen to evaluate thrombolytic therapy using
incremental cost-benefitanalysis. This approach reduces the
number of assumptions necessary to construct a model of
thrombolytic therapy. For example. there is no need to es-
timate the cost of standard care for acute myocardial in-
farction,
Several long-term medical care costs and potential
nonmedical care costs and savings are excluded from this
analysis. These include capital costs associated with ex-
pansion of the emergency transport system and with con-
struction of additional cardiac catheterization laboratories
and facilities for open heart surgery. training and salary
expenses for additional physicians and support personnel to
staff these facilities and opportunity costs triggered by a
surge or demand on existing facilities. On the other hand,
because a high percentage of patients treated with throm-
bolysis may receive angioplasty or surgery early in their
course, these costs may be offset in part by the prevention
or future cardiac events and a reduction in future needs for
these procedures. Finally, possible cost savings because of
reduced disability and higher rates of return to work may
become attributable to thrombolysis/reperfusion therapy.
If thrombolytic therapy becomes a new standard of care
for acute myocardial infarction, as now appears likely, then
a comprehensive cost analysis. including the considerations
mentioned. is indicated. The results of such an analysis.
expressed in the familiar " dollars per year of life saved,"
would greatly facilitate cost-benefit comparisons between
thrombolysis and other medical technologies.
The Benefit s of Thrombolytic Therapy:
Some Caveats
The model should not be used as a substitute for in-
dividualized decision making, The model was designed
to examine overall benefits and medical care costs from
thrornbolysis/reperfusion therapy. It may not be applicable
to individual patients. Occasional patients with a " stuttering
infarct" may have substantial salvage of myocardium as
late as 6 hours after the onset of infarction. Others, with
very severe ischemia due to sudden total occlusion, the
absence of collateral vessels and high myocardial oxygen
requirements. may have extensive and virtually complete
infarction after 1 or 2 hours. In addition. the clinical spec-
trum of reocclusion is quite broad. ranging from an asyrnp-
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tomatic event to cardiogcnic shock and death. The model
is not meant to substitute for physician-initiated treatment
strategies designed on behalf of individual patients.
Thrombolytic therapy and coronary angioplasty. We
have assumed that the clinical benefits of thromboly-
sis/reperfus ion therapy are primarily determined by the tim-
ing of reperfusion. There is some evidence that the quantity
of anterograde blood flow after reperfusion may also affect
left ventricular function in the chronic postinfarction period.
Sheehan et al. (43). in a nonrandomized study of intracor-
unary streptokinase, found significantly greater improve-
ment in infarct region hypokinesia in patients having a post-
reperfusion coronary lumen > 0.4 mm. O'Neill's random-
ized trial (15) of intracoronary streptokinase and primary
ungioplasty found the latter to be more effective in alle-
viating underlying coronary stenosis and hence improving
anterograde blood tlow. This was correlated with signifi-
cantly greater increases in global ejection fraction (8 ± 7
versus I ± 6%. p < 0.001). However. this effect can also
be attributed to the presumably shorter delay in the onset
of repcrfusion associated with primary angioplasty. If aug-
mented blood flow after reperfusion is indeed found to have
an independent effect on the benefits of thrombolytic ther-
apy, then the aggressive protocols' costs per additional sur-
vivor would decrease relative to that of the conservative
protocols.
The duration of time between pharmacologically me-
diated reperfusion and secondary coronary angioplasty is
likely to affect the benefits of aggressive strategies utilizing
angioplasty, because the risk of reocclusion probably re-
mains high until angioplasty is performed. As stated pre-
viously, we have assumed that secondary angioplasty is
performed immediately after rcpcrfusion in all aggressive
protocols: the risk of reocclusion is thus immediately re-
duced. As data becomeavailable regarding the rate of " early"
reocclusion, that is. reocclusion occurring before angie-
plasty can be accomplished. this will be incorporated into
the model.
Potential benefit of reperfusing infarcted myocar-
dium, We have assumed that there is no benefit associated
with the reperfusion of infarcted myocardium. However.
even very late reperfusion may in fact protect, through col-
lateral flow. adjacent myocardium against future occlusion
of the artery that perfuses it, Further investigation is required
to study this possibility.
lnfluence of preexisting left ventricular dysfunction.
The model is designed to analyze patients with normal left
ventricular function before the incident infarct. However.
in patients with a previous infarct or diminished left ven-
tricular function for any reason. the same infarct might be
associated with higher mortality. Therefore, the use of
thrornbolysis/reperfusion therapy in such patients might be
associated with greater marginal benefits and, hence, lower
cost per additional survivor.
Future benefits. All calculations are based for simplicity
on the first year after acute myocardial infarction. Undoubt-
edly. thrornbolysis/repcrfusion therapy extends survival be-
yond the first year in many cases. Our calculations under-
estimate total benefits in these cases. Table \} shows. in a
qualitative sense. how this and other previously discussed
simplifying assumptions might influence cost/benefit rela-
tions for thrombolysis/reperfusion therapy.
Table 9, Add itional Factors That Could Affect the Cost-Effectiveness of
Thrornbolysis/Reperlusion Therapy
- ---------------------
More effective outpatient delivery of thrombolytic drugs ( I ,
More effective inpatient delivery of thrombolytic drugs ( :!)
Expansion of inpatient lacilhies (3)
Considera tiun or morbid complications (4 )
Improved survival beyond the first year after myocardial
infarction <51
Employment statu:..after infarction (6)
Preexisting LV dysfunction (7 )
Future cifccts on collateral Row ( ~)
Cost per
Tntal Total .'\ l1ditiunal
Cosh Benefits Sur vivors
1 i II
l! T 1
'I I i
i II 1
il ! II
II i L
i 1 1
l! i L
1 = Expanded emergency transport systems: programs involving the administration of thrombolytic agents
in ambulances or in the home: patient education programs. 2 = Improved triage: heightened staff awareness:
use of protocols [or rapid diugnosi« and drug adminisrrution. :> '" Expansion of existing catheterization and
surgical suites and coronary care units: increased staffing and the training of additional personnel. 4 = Increased
cost« of blood transfusions and transfusion-related complications. 5 = Our model is designed to analyze only
incremental I year survival. f> = Successful myocardial salvage may improve functional capacity and the ability
10 return to work. 7 = Marginal benefits of thrombolysis/reperfusion therapy are relatively high in patients
with preexisting left ventricular (LV) dysfunction. 8 = Repertusion may allow for the formation of improved
collateral flow to myocardium perfused by other stenosed coronary vessels. i = Increased: t = decreased.
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Patient Population Applicable to This Analysis
Although nearly 1.5 milliun patients develop acute myo-
cardial infarction in the United States annually. thrombolytic
therapy will not be suitable for many, At least one-quarter
of these patients die before reaching a hospital. Among those
who reach the hospital. some patients have contraindications
to thrombolysis, and it is assumed that the treatment has
little proved value for those arriving long after onset of
infarction. Furthermore, the role of thrombolytic therapy in
patients having nondiagnostic ST and T wave abnorma lities
and in elderly patients remains to be defined. Thus. at this
time, thrombolytic therapy can probably be considered for
the treatment uf :sAO% of patients with acute myocardial
infarction. regardless of considerations or its cost-
effectiveness.
Directions jor the Future
The assumptions used to construct our model arc based
on data available in early 1987. Thrornbolysis/reperfusion
therapy can be expected to evolve in several directions in
the near future. Protocols encouraging the rapid intravenous
administration of thrombolytic drugs may he develop ed for
the hospital. for ambulances. fi rst aid stations and even for
the horne. Research and development of new thrombolytic
agents are likely to continue. Success rates with primary
and secondary coronary angioplasty are likely to improve
as experience with this technique increases. And, of course,
the cost of rt-PA and its congeners will directly affe ct the
overall cost-effectiveness of tbrombolysis/rcperfusion ther-
apy.
An important advantage of a model such as the nne used
in this analysis is that it can be updated readily to incorporate
such evolutionary changes and to include the results of new
investigations. For example. several characteristics of new
thrombolytic agents will undoubtedly affect the relations
between the costs and benefits of thrombolytic therapy. One
new agent. acylated streptokinase. appears to be most ef-
fective when given as an intravenous bolus (44); such in-
travenous bolus therapy may reduce procedural delay and
thereby increase benefits. Other agents or modifications of
currently available agents with greater thrombolytic effi-
cacy. a lower risk of bleeding and a lower incidence of
reocclusion would also exert favorable effects. For example.
prolonged administration of low doses of rt-PA may reduce
the incidence of reocclusion and. hence, the need for me-
chanical revascularization (45).
Quality of life and thrombolysis. We have not at-
tempted to estimate the quality of life after thrombolytic
therapy because of the inconsistent relation between left
ventricular ejection fraction and quality of life. Quality of
lire after acute myocardial infarction depends on llIany fac-
tors other than ejection fraction. and may even hc inl1ucnced
by the form of mechanical revascuJaril.ution (angioplusty
LAFFLL t:T 1\ 1
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versus surgery) chosen after thrombolysis (46). Further re-
search will be required to clarify these relations.
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